Personalised medicine for hypertension

BMJ (Online)

Volumn 343, Issue 7825, 2011, Pages

  Brown, Morris J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN; SODIUM ION;

AGE; DRUG EFFICACY; DRUG INDICATION; EDITORIAL; ETHNIC DIFFERENCE; HUMAN; HYPERTENSION; LABORATORY TEST; MEDICAL SOCIETY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PLASMA RENIN ACTIVITY; PRESCRIPTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; UNITED KINGDOM;

ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; RENIN;

EID: 84859008493     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4697     Document Type: Editorial

References (11)

1. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults.NICE guideline. Draft for consultation. 2011. www.nice. org.uk/nicemedia/live/12167/53225/53225.pdf.
2. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens 2010;23:1031-7.
3. Gupta AK, Poulter NR, Dobson J, Eldridge S, Cappuccio FP, Caulfield M, et al. Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. Am J Hypertens 2010;23:1023-30.
4. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, et al. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 2010;23:1014-22.
5. Brown MJ. Heterogeneity of blood pressure response to therapy. Am J Hypertens 2010;23:926-8.
6. Ehret G, Munroe P, Rice K, Bochud M, Johnson A, Chasman D, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature [forthcoming].
7. Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33. (Pubitemid 47310975)
8. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of anti-hypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13. (Pubitemid 29271745)
9. Deary A, Schumann A, Murfet H, Haydock S, Foo R, Brown M. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002;20:771-7. (Pubitemid 34913723)
10. Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007;25:951-8. (Pubitemid 46573113)
11. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007;116:268-75. (Pubitemid 47196562)